Changing factories is usually not the hard part — qualifying the ingredients the new factory wants to use is. When an incoming manufacturer proposes a “same INCI” replacement, or sources your formula’s raw materials from a different supplier than your previous plant used, the product you validated no longer exists until you re-prove it. This guide gives brand owners and sourcing managers a practical qualification sequence: what to compare, what evidence to request, which controls are non-negotiable, and how to plan a timeline that survives a real launch date. It applies to body care and skincare programs alike — lotions, creams, body washes, cleansers, and scalp or body serums.
Why a factory change becomes an ingredient qualification project
The moment production moves, three things change at once: the supplier base, the material grades those suppliers carry, and the process conditions the bulk is made under. An INCI name is a naming convention, not a specification — it will not tell you the assay level, the carrier, the salt form, the impurity profile, the particle size, or the preservative system that actually sits in the drum.
- INCI is not a specification. The same INCI name can be supplied at different activity levels, in different carriers, with different residual solvents or isomer ratios.
- The name hides the diluent. For supplied raw materials, water, ethanol and other diluents or solvents are normally not part of the INCI name, so a “match” can arrive at a very different solids content.
- Blends are ordered by weight, not fixed. For materials formed by mixing, the INCI declaration lists components in descending order — a re-ordered blend is a different material in practice.
- Hydration state is not declared. An INCI name does not indicate whether the material is anhydrous or hydrated, which matters for pH and stability.
- Performance drift is invisible on paper. Viscosity curves, colour, odour and sensory feel can shift without a single line of the ingredient list changing.
That is why the working assumption should be: a new factory means new raw materials until proven otherwise.
Fast self-check: what kind of change are you actually making?
- If only the filling or packaging site changes and the bulk, formula, raw material suppliers and specs stay identical → run a packaging compatibility and filling trial. Full re-qualification is not required, but batch records, artwork and label content still need review.
- If the new factory keeps your formula but buys its own raw materials → treat every material as a supplier change and run full ingredient qualification.
- If the INCI is identical but the supplier, grade, carrier or purity differs → COA comparison, bench trial and key stability testing. No exceptions.
- If the fragrance base version, IFRA certificate or allergen declaration changes → re-assess exposure, review allergen warnings, decide on a tolerance re-test, and update the product safety report and any registration files.
- If a performance claim hangs on that ingredient (reduces breakage, anti-dandruff, hair loss, “boosts collagen”) → you need finished-product evidence, or the claim comes off the artwork.
- If the replacement is a botanical or “natural” material → confirm botanical name, plant part, origin and harvest batch, extraction method, whether it is decolourised, deodorised, fractionated, FCF or standardised, plus a GC/MS or fingerprint chromatogram.
- Boundary cases: if the change pushes claims toward a drug-like mechanism (follicle stimulation, hair growth, treating dandruff), or the target market requires a new filing, stop and get classification and regulatory review before you book a pilot run.
“Same INCI” is not a specification — what actually has to match
| Parameter |
Why it can change the finished product |
What to compare |
| Assay / active content |
Changes cost-in-use and the real concentration in formula |
COA assay range vs your current spec; adjust dosage if the active level differs |
| Carrier and solvent system |
Alters solids, viscosity, drying time and preservative demand |
COA composition, TDS, and the diluent that is not declared in the INCI name |
| Salt form, pH and neutralisation |
Drives pH drift, thickening behaviour and stability |
pH of a 1–10% dispersion, plus your formula’s pH after 24 h and after 4 weeks |
| Impurities |
Heavy metals, residual solvents, monomers and 1,4-dioxane or ethylene oxide risk |
COA impurity section and a written statement of the manufacturing route |
| Particle size / polymer grade |
Affects film, feel, whitening on rub-in, and suspension stability |
TDS particle size or viscosity grade; visual and sensory side-by-side |
| Preservative system in the raw material |
Stacks with your preservative and can exceed limits or kill the challenge test |
Full composition disclosure and a total-preservative-load calculation |
| Colour and odour |
Shows up immediately in an unscented or white base |
Visual and olfactory comparison against a retained reference sample |
| Grade |
Technical grade is not cosmetic grade |
Grade statement plus cosmetic suitability declaration on the COA/TDS |
The qualification sequence — run it in this order
- COA-to-COA comparison. Put the old and new certificates side by side against your existing specification. Any parameter that is outside spec, or missing, is a stop sign, not a note.
- Bench trial at lab scale. Make the formula with the replacement at the same use level, and one at an adjusted level if the assay moved. Retain a control made with the original material.
- Key stability. At minimum: accelerated and real-time samples for viscosity, pH, appearance, odour and emulsion integrity, plus freeze–thaw cycling for emulsions. Extend to full duration if the material is a film former, emulsifier or active.
- Physical and performance proxies. Because “cleans well” or “feels light” cannot be measured every batch, control the key formulation state instead — pH, viscosity, foam and sensory against the reference — and verify those proxies periodically against the validated benefit.
- Preservative efficacy decision. If the pH, water activity or preservative system shifted, re-run a challenge test. Do not assume the previous result transfers.
- Claims and commercial review. Re-check every claim touching the changed ingredient, then compare cost-in-use and supply risk before signing off. A cheaper material that needs a higher use level is not cheaper.
Evidence to request from the incoming factory (minimum pack)
A) Identity and supplier documentation
- Request: Full identity sheet per material.
Evidence: INCI name, CAS/EC where applicable, supplier name, grade, composition and carrier, purity and impurity profile.
Acceptance: Complete for 100% of materials in the formula, with no “proprietary blend” gaps that block safety review.
- Request: Current TDS and SDS per material.
Evidence: Version-dated documents matching the supplier actually used.
Acceptance: Document date within 3 years and supplier name matching the COA.
- Request: Change notification commitment.
Evidence: Written clause covering supplier, origin, plant species, extraction or standardisation, fragrance base version, solvent, colorant, antioxidant, and packaging component changes.
Acceptance: Signed agreement with a defined notice period before your next production run.
B) Testing and substantiation
- Request: Batch COA for the exact lot to be used.
Evidence: Lot number, test methods, specification limits, actual results, release signature.
Acceptance: Lot number traceable to the drums delivered to the line.
- Request: Stability protocol and results for the reformulated bulk.
Evidence: Test conditions, durations, and results for viscosity, pH, appearance, odour and emulsion integrity.
Acceptance: No result outside agreed specification at the accelerated timepoint.
- Request: Microbiological testing and preservative efficacy.
Evidence: Total aerobic count, yeast and mould, specified organisms, plus challenge test where triggered.
Acceptance: Results within your micro spec and challenge test pass against your acceptance criteria.
- Request: Safety substantiation file for the finished product.
Evidence: The seven core answers — identity, function and use level, toxicology endpoints, market restrictions, impurities where relevant, supplier data, and history of safe use.
Acceptance: File references each raw material and its concentration, and covers every target market.
C) Labelling and claims guardrails
- Request: Final INCI list and allergen declaration.
Evidence: Declared order by concentration, allergens above the labelling threshold, and the fragrance IFRA certificate with its version number.
Acceptance: Matches the qualification formula exactly, not a similar one.
- Request: Claim-by-claim evidence mapping.
Evidence: A claim matrix separating ingredient facts (“contains niacinamide”) from finished-product claims (“improves scalp comfort”), each with its evidence ID.
Acceptance: No claim on pack or listing without a mapped evidence line.
- Request: Market restriction check for each ingredient.
Evidence: Restricted and prohibited substance screening against the target market’s annexes and positive lists, plus a written statement that the material is not a colour additive requiring separate certification.
Acceptance: Signed screening sheet per market, dated after the formula was locked.
D) QA, traceability and audit readiness
- Request: Batch record template and traceability flow.
Evidence: Lot numbers for every raw material, weighing records, in-process checks, and retained sample policy.
Acceptance: Any finished batch can be traced to raw material lot within one working day.
- Request: In-process and release specification.
Evidence: Test items, methods, frequency and limits for pH, viscosity, appearance and odour.
Acceptance: Every parameter has a numeric limit and an approved method.
- Request: Post-change surveillance plan.
Evidence: Adverse event and complaint monitoring for the first three commercial batches after the change.
Acceptance: A named owner and a review date in the project plan.
Do NOT cut — the red lines during a factory change
- Do not cut key stability because the swap is “only a supplier change”. Stability is the cheapest place to discover a viscosity drift.
- Do not cut preservative efficacy testing when pH, water activity or the preservative system moved.
- Do not accept a COA without a lot number, test method and specification limit. An unsigned certificate is marketing material.
- Do not accept “FDA approved” as a compliance statement. In the US, cosmetic ingredients other than colour additives are generally not pre-approved; the brand carries the safety substantiation responsibility.
- Do not extrapolate ingredient studies to finished-product claims. An ingredient paper does not make your lotion “clinically proven”.
- Do not let the allergen declaration slide when a fragrance base version changes — the label warning and the safety file both move with it.
- Do not skip packaging compatibility on the assumption that the pack “worked before”. A new bulk viscosity meets a new pump.
- Do not treat botanical identity as optional. Species, plant part, origin and extraction method are part of the specification, not the story.
Timeline: qualifying replacement ingredients before production
Fastest safe path (about 10–14 weeks)
- Weeks 0–1 — Specification and document comparison. Buyer: send the current specification and a retained reference sample. Manufacturer: return COAs and TDS for every replacement. Evidence: a signed gap list showing each parameter outside or missing from spec.
- Weeks 1–3 — Bench trial. Buyer: approve the trial brief and use levels. Manufacturer: produce trial batches against a retained control. Evidence: trial report with pH, viscosity, appearance and sensory comparison.
- Weeks 3–4 — Packaging compatibility and label lock. Buyer: lock pack components and artwork. Manufacturer: run fill, leak and pump-delivery checks on the trial bulk. Evidence: compatibility report and an approved artwork file.
- Weeks 4–10 — Compressed stability. Buyer: accept a shortened accelerated protocol in writing. Manufacturer: run accelerated and freeze–thaw testing. Evidence: interim and final stability report. Only compress duration, never the test items.
- Weeks 10–12 — Pilot run. Buyer: attend or review the pilot. Manufacturer: produce the pilot batch and pull release samples. Evidence: pilot batch record and release results.
- Weeks 12–14 — Documentation handoff. Buyer: verify the pack matches the qualified formula. Manufacturer: deliver the full evidence pack. Evidence: signed-off dossier and retained samples.
Standard path (about 18–26 weeks)
- Weeks 0–2: specification alignment, document comparison and supplier qualification questionnaires.
- Weeks 2–5: bench trials, an iteration cycle if the first trial misses viscosity or sensory, plus full packaging compatibility including 4-week label adhesion.
- Weeks 5–18: full stability programme with real-time data, microbiological testing and challenge testing where triggered, and safety file compilation per market.
- Weeks 18–21: pilot run, in-process validation and release testing.
- Weeks 21–26: label and claims review against the final formula, filings or notifications where the market requires them, documentation handoff, and post-change surveillance setup.
Dependencies that break the schedule more often than testing does: packaging arriving late, artwork changing after stability starts, and a formula still being adjusted while the safety file is being written.
Common failure modes — and how to prevent them
- Viscosity drift at week three.
Symptom: a lotion thickens or thins after filling and the pump no longer dispenses the target dose.
Root cause: a different polymer grade or neutralisation level in the replacement raw material.
Prevention: compare viscosity grade and pH of dispersion before the trial, not after.
What to request: TDS viscosity grade, pH of a standard dispersion, and the trial viscosity curve over 4 weeks.
- Packaging compatibility failure.
Symptom: leakage at the pump collar, a dip tube that cannot pick up a thicker bulk, label edges lifting, or a scent shift in the bottle after 4 weeks.
Root cause: bulk viscosity and surface chemistry changed while the pack stayed the same; fragrance components interacted with the plastic or adhesive.
Prevention: run a compatibility trial on the new bulk with the actual production components, including gasket and coating, before printing labels.
What to request: written compatibility report covering pump, gasket, dip tube, coating and label adhesive, with 4-week and 8-week observations.
- Documentation failure.
Symptom: the launch is ready but the retailer, distributor or customs agent holds the shipment for a missing or mismatched document.
Root cause: missing COA, SDS or stability/micro report; INCI on the artwork not matching the qualified formula; claims on pack with no supporting evidence file.
Prevention: build one controlled dossier per SKU and version it with the formula.
What to request: a complete document set with version numbers and dates, plus a signed statement that the INCI declaration matches the production formula.
- Fragrance change without allergen review.
Symptom: label warnings are incomplete, or a consumer complaint pattern emerges in the first weeks.
Root cause: a new fragrance base version with a different allergen profile was treated as a like-for-like swap.
Prevention: re-assess exposure, decide explicitly whether a tolerance re-test is needed, and update the safety file and warnings together.
What to request: IFRA certificate with version number, full allergen declaration, and a written exposure re-assessment.
- Claim creep onto the ingredient story.
Symptom: marketing copy states a health outcome the formula was never tested for.
Root cause: an ingredient fact was upgraded into a finished-product claim without new evidence.
Prevention: keep ingredient stories and finished-product claims in separate columns of one claim matrix, each with its own evidence reference.
What to request: the claim matrix with evidence IDs and the market classification opinion for the highest-risk claim.
- Preservative system stacking.
Symptom: the challenge test fails, or a preservative exceeds its permitted concentration in the market.
Root cause: the replacement raw material carries its own preservative that was not declared or counted.
Prevention: total the preservative load across all materials before finalising the formula.
What to request: full composition of each raw material, including preservatives, plus a total-load calculation against the market limit.
- Botanical identity slip.
Symptom: colour or odour differs batch to batch and the “natural” claim looks shaky.
Root cause: a different species, plant part, origin or extraction method supplied under a similar trade name.
Prevention: specify botanical name, plant part, origin, extraction and standardisation in the purchase specification.
What to request: botanical identity statement, GC/MS or fingerprint chromatogram, and an adulteration risk note.
Copy-paste request checklist
Paste this into an email to a prospective manufacturer; it works as a first-round qualification request.
Share your current specification and a retained reference sample for each material.
Confirm whether any raw material supplier or grade differs from our current plant.
Provide INCI, CAS/EC, grade, carrier and impurity profile for every replacement.
Attach batch COAs with lot number, test method and specification limits.
Attach current TDS and SDS, version-dated, matching the named supplier.
Confirm the preservative content of each raw material for total-load calculation.
Provide a written statement of the manufacturing route where impurity risk exists.
State whether a fragrance base version, IFRA certificate or allergen list changed.
Attach the full allergen declaration against our target market thresholds.
Test the reformulated bulk against a retained control and report pH and viscosity.
Report appearance, odour and sensory comparison for the trial batch.
Run freeze-thaw and accelerated stability, and share interim results.
Review whether a preservative challenge test is required after the change.
Confirm microbiological limits and testing frequency for the new bulk.
Run a packaging compatibility trial with the actual pump, gasket and label.
Approve artwork only after the qualified formula and INCI list are final.
Map every pack claim to an evidence reference on a claim matrix.
Confirm which market filings or notifications the change triggers.
Provide the batch record template and raw material traceability flow.
Lock the pilot batch date and name the release-testing owner.
Deliver the full evidence pack, versioned and dated, before first production.
Review adverse event monitoring for the first three commercial batches.
Frequently asked questions
Can we keep the same formula if the new factory uses a different supplier for the same INCI?
You can keep the formula on paper, but you cannot assume the product is unchanged. Different suppliers of the same INCI can differ in active content, salt form, solvent, particle size, polymer grade, impurities, colour, odour and the preservative carried in the drum. The minimum response is a COA-to-COA comparison, a bench trial against a retained control, key stability, and a check of pH, viscosity, appearance and sensory. If any of those move, the formula needs adjusting before it goes to pilot.
How long should ingredient re-qualification take before we can produce?
For a straightforward swap in a stable emulsion, plan 10 to 14 weeks on a compressed path, and 18 to 26 weeks on a standard path with real-time stability and full market documentation. The compression should come from shortening test duration with written acceptance, never from removing test items. Packaging lead time and artwork changes usually delay projects more than the lab work does.
Do we need a new challenge test after changing a raw material?
Not automatically — but you must make the decision explicitly rather than by default. If the change alters pH, water activity, the preservative system, or the preservative load contributed by the raw material, a new preservative efficacy test is usually the right call. Record the reasoning either way, because a buyer or auditor will ask for it later.
Is “clinically proven” acceptable if the ingredient supplier has a clinical study?
No. A study on the raw material does not establish the performance of your finished product, because the concentration, interactions and use conditions are different. You can state that the formula contains a clinically tested ingredient, provided the wording is carefully contextualised and does not imply the finished product carries the same result. Anything stronger needs finished-product evidence.
Does the change require a new registration or filing?
It depends on the market and on what actually changed. A supplier change with an identical specification may only require an internal file update; a fragrance or preservative change can require updates to the product safety report, safety substantiation records and notification files. Confirm the requirement per market before the pilot run, not after the labels are printed. This guide is informational only and is not legal advice.
Next step
If you are moving a body care or skincare line to a new manufacturing partner, send us the formula category, the materials you expect to replace, your target markets, packaging direction and launch window. We will return a qualification plan with the document set, test matrix and realistic dates — so the ingredient decisions are settled before the pilot batch, not after.
Request a Quote
LAEYO
Hi, I'm your LAEYO representative, hope you like this blog post.
With more than 20 years of experience in OEM/ODM/Private Label Cosmetics, I'd love to share valuable knowledge related to cosmetics & skincare products from a top-tier Chinese supplier's perspective.